CHRS - Coherus BioSciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
1.25B
Enterprise Value 3
1.27B
Trailing P/E
N/A
Forward P/E 1
7.54
PEG Ratio (5 yr expected) 1
0.53
Price/Sales (ttm)
5.37
Price/Book (mrq)
22.27
Enterprise Value/Revenue 3
5.47
Enterprise Value/EBITDA 6
251.51

Trading Information

Stock Price History

Beta (3Y Monthly) 2.90
52-Week Change 378.64%
S&P500 52-Week Change 318.50%
52 Week High 323.91
52 Week Low 38.32
50-Day Moving Average 318.08
200-Day Moving Average 319.35

Share Statistics

Avg Vol (3 month) 31.17M
Avg Vol (10 day) 31.17M
Shares Outstanding 570.13M
Float 62.52M
% Held by Insiders 13.54%
% Held by Institutions 197.45%
Shares Short (Nov 29, 2019) 49.08M
Short Ratio (Nov 29, 2019) 48.35
Short % of Float (Nov 29, 2019) 415.31%
Short % of Shares Outstanding (Nov 29, 2019) 412.94%
Shares Short (prior month Oct 31, 2019) 49.15M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Sep 30, 2019

Profitability

Profit Margin -5.16%
Operating Margin (ttm)0.96%

Management Effectiveness

Return on Assets (ttm)0.60%
Return on Equity (ttm)-35.05%

Income Statement

Revenue (ttm)232.22M
Revenue Per Share (ttm)3.27
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)-106.38M
EBITDA 5.05M
Net Income Avi to Common (ttm)-11.99M
Diluted EPS (ttm)-0.17
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)170.49M
Total Cash Per Share (mrq)2.43
Total Debt (mrq)190.64M
Total Debt/Equity (mrq)340.30
Current Ratio (mrq)3.34
Book Value Per Share (mrq)0.80

Cash Flow Statement

Operating Cash Flow (ttm)-36.72M
Levered Free Cash Flow (ttm)-6.52M